Molecular Partners Posts 2025 Results, Advances Radio-DARPins and Oncology Pipeline

The latest announcement is out from Molecular Partners ( (MOLN) ).

On March 12, 2026, Molecular Partners reported its 2025 audited financial results and corporate highlights, underscoring a cash position of CHF 93.1 million that is expected to fund operations into 2028 and support the expansion of its oncology pipeline. The company also published its 2025 Annual Report, signaling continued investment in clinical development of its key programs.

The firm initiated a U.S. Phase 1/2a trial of its first Radio-DARPin therapy MP0712 in 2025 for small cell lung cancer and other DLL3-expressing neuroendocrine tumors, following encouraging early imaging and dosimetry data presented in January 2026 that showed specific tumor uptake and limited healthy-tissue exposure. A second Radio-DARPin, MP0726 targeting mesothelin, is advancing toward first-in-human imaging as Molecular Partners broadens its radiotherapeutics platform, supported by a new scientific advisory board chaired by nuclear medicine expert Prof. Ken Herrmann.

To strengthen its radiopharmaceutical capabilities, Molecular Partners signed a non-exclusive development agreement with radioisotope specialist Eckert & Ziegler, enabling its Radio-DARPin candidates to use a range of alpha-emitting isotopes such as 225Ac and underpinning further preclinical data to be presented in March 2026. This agreement, combined with its partnership with Orano Med, positions the company as an emerging player in targeted alpha therapy for solid tumors.

Beyond radiotherapy, an investigator-initiated randomized Phase 2 trial of tumor-localized CD40 agonist MP0317 is enrolling patients with advanced cholangiocarcinoma in France, testing the agent in combination with durvalumab plus gemcitabine-cisplatin against standard-of-care alone. Earlier Phase 1 data completed in 2024 showed tumor-localized CD40 activation and remodeling of the tumor microenvironment, supporting the hypothesis that MP0317 could enhance efficacy while limiting systemic toxicity.

In hematologic oncology, Molecular Partners’ tetra-specific T cell engager MP0533 is in an ongoing Phase 1/2a trial for relapsed or refractory acute myeloid leukemia and related disease, with 2025 data from the ASH meeting indicating that densified dosing is tolerable and associated with improved drug exposure and antitumor activity, particularly in patients with lower blast counts. The company is engaging with consortia, key opinion leaders, and regulators to refine MP0533’s development path, with a further clinical update expected in the first half of 2026, reflecting growing external interest in combination strategies.

The most recent analyst rating on (MOLN) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Molecular Partners stock, see the MOLN Stock Forecast page.

Spark’s Take on MOLN Stock

According to Spark, TipRanks’ AI Analyst, MOLN is a Neutral.

The score is primarily weighed down by weak financial performance (near-zero TTM revenue, ongoing losses, and significant negative free cash flow) despite low leverage. Technicals are slightly negative in the near term with muted momentum, and valuation provides limited support because the company is loss-making and no dividend yield data is available.

To see Spark’s full report on MOLN stock, click here.

More about Molecular Partners

Molecular Partners AG is a clinical-stage biotechnology company based in Zurich-Schlieren, Switzerland, and Concord, Mass., developing a novel class of protein drugs called DARPin therapeutics. Its pipeline focuses on targeted radiopharmaceuticals, tumor-localized immunotherapies, and multispecific T cell engagers aimed at difficult-to-treat solid and hematologic cancers, with collaborations including Orano Med and Eckert & Ziegler.

Average Trading Volume: 4,724

Technical Sentiment Signal: Buy

Current Market Cap: $193.8M

Find detailed analytics on MOLN stock on TipRanks’ Stock Analysis page.